Randomized Ph 2 Trial Of Paclitaxel/Carboplatin /Bevacizumab + PF-3512676 And P/C/B Alone In Advanced Nonsquamous NSCLC
NCT00313768
Terminated
To assess the efficacy and safety of PF-3512676 administered in combination with paclitaxel, carboplatin and bevacizumab as first-line treatment in patients with locally advanced or metastatic nonsquamous non-small cell lung cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/24/2009
Locations: Pfizer Investigational Site, Austin, Texas +5 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Gemcitabine/Oxaliplatin (GEMOX) vs Carboplatin/Paclitaxel (CP) in Non-Small Cell Lung Cancer (NSCLC)
NCT00087802
Completed
The purpose of this study is to compare combination treatment of gemcitabine + oxaliplatin (GEMOX) with carboplatin + paclitaxel (CP) to determine if there is a difference in response and safety between the two drug combinations for the treatment of advanced non-small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2009
Locations: Texas Cancer Center - Abilene, Abilene, Texas +27 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)
NCT00088088
Completed
This study is for patients who have Stage IIIb or Stage IV NSCLC and have never had chemotherapy before for their disease. The first phase of the study recently completed and for the second phase of the study patients are randomly assigned to receive either paclitaxel and carboplatin or paclitaxel and carboplatin and study drug (STA 4783). Treatment will be every 3 weeks for 6 cycles.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/03/2008
Locations: Presbyterian Hospital, Dallas, Texas
Conditions: Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Register for Updates
Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ (DCIS)
NCT00669747
Unknown
The primary objective of this study is to compare the safety of 100 mg carboplatin administered intraductally once on Day 1 or twice on Days 1 and 15 in women with ductal carcinoma in situ (DCIS) undergoing surgical management 2 to 4 weeks following the Day 15 intraductal infusion. Secondary objectives are to characterize the biologic and clinical effects with respect to: pharmacokinetics, extent of disease on MRI and mammogram, histopathological assessment of DCIS, and biomarker measurement of... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/01/2008
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Ductal Carcinoma In Situ
Register for Updates
Paclitaxel With or Without Carboplatin in Treating Women With Metastatic Breast Cancer
NCT00025688
Unknown
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if paclitaxel is more effective with or without carboplatin in treating stage IV breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of paclitaxel with or without carboplatin in treating women who have stage IV breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/23/2008
Locations: Texas Cancer Care, Fort Worth, Texas +2 locations
Conditions: Breast Cancer
Register for Updates
A Trial of Carboplatin and Gemcitabine Versus Gemcitabine Alone in Patients With Non-Small-Cell Lung Cancer
NCT00190710
Completed
To determine and compare the median survival produced by combined Gemcitabine plus Paraplatin versus Gemcitabine as a single-agent in patients with NSCLC and a PS equal to 2.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/10/2007
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas
Conditions: Non-Small Cell Lung Cancer
Register for Updates
PH 1 Evaluation Of Oral CI-1033 In Combination With Paclitaxel/ Carboplatin As 1st Line Chemotherapy In NSCLC Patients
NCT00174356
Completed
The main purpose of this study is to evaluate the overall safety and maximum dose of CI 1033 in combination with paclitaxel and carboplatin in patients with NSCLC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/06/2006
Locations: Pfizer Investigational Site, Houston, Texas
Conditions: Carcinoma, Non-Small Cell Lung
Register for Updates
ALIMTA Plus Carboplatin as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial.
NCT00051493
Completed
The purpose of this study is to evaluate the effects (good and bad) of LY231514 (ALIMTA) and Carboplatin on you and your non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2006
Locations: Not set, Houston, Texas
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
A Phase 2 Trial of Antisense Nucleotide to PKC-Alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer.
NCT00042679
Completed
The purposes of this study are to determine the following: Whether LY900003 plus gemcitabine and carboplatin can make your tumor smaller or disappear, and for how long. If treatment with LY900003 plus gemcitabine and carboplatin can help you live longer. The safety of LY900003 plus gemcitabine and carboplatin and any side effects that might be associated with the combination of these three drugs. How LY900003 is distributed and broken down by your body when it is given with carboplatin and g... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2006
Locations: Not set, Lubbock, Texas
Conditions: Carcinoma, Non-Small-Cell Lung, Pulmonary Neoplasms, Neoplasms, Lung
Register for Updates